TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8961074

Group type: EXPERIMENTAL
Intervention: Moexipril 7.5 mg once daily, increased to 15 mg once daily after 6 weeks if SDBP > 90 mm Hg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily, increased to 50 mg twice daily after 6 weeks if SDBP > 90 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moexipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moexipril and Captopril
Number of subjects: 0
Study: 2509064

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Partial parenteral plus enteral nutrition by tube feeding (PPN/EN)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both TPN and PPN/EN
Number of subjects: 22
Study: 786349

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Phenoperidine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 113
Study: 30995970

Group type: EXPERIMENTAL
Intervention: Scleral lenses with Dk/t of 100 Barrer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scleral lenses with Dk/t of 140 Barrer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scleral lenses with Dk/t of 160 Barrer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patched eyes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unpatched eyes
Number of subjects: 10
Study: 28107763

Group type: EXPERIMENTAL
Intervention: I-SCAN
Number of subjects: 61

Group type: COMPARATOR
Intervention: HD-WLE
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Inspection time
Number of subjects: 61
Study: 26077768

Group type: EXPERIMENTAL
Intervention: Partially defatted Brazil nut flour (13 g/day providing 227.5 μg of selenium/day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Dyed cassava flour (placebo)
Number of subjects: 77
Study: 23161895

Group type: EXPERIMENTAL
Intervention: Enhanced alerts with patient's most recent potassium and creatinine levels
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Unmodified alerts
Number of subjects: 1029
Study: 21663428

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS MPH) 18, 36, and 54 mg QD after high-fat breakfast
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS MPH) 18, 36, and 54 mg QD after normal breakfast
Number of subjects: 32

Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (IR MPH) 5, 10, and 15 mg TID after normal breakfast
Number of subjects: 32

Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (IR MPH) 5, 10, and 15 mg TID after fasting
Number of subjects: 32
Study: 19239703

Group type: EXPERIMENTAL
Intervention: Decremental PEEP titration after ARM
Number of subjects: 57

Group type: COMPARATOR
Intervention: Table-based PEEP (control)
Number of subjects: 57
Study: 16107868

Group type: EXPERIMENTAL
Intervention: Vacuum constriction device (VCD) used daily for 9 months (Group 1, N=74)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Observation without any erectogenic treatment (Group 2, N=35)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Successful users of VCD (60 patients)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nonresponders to VCD (14 patients)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (Group 2, N=35)
Number of subjects: 109
Study: 15204157

Group type: EXPERIMENTAL
Intervention: ELA-Max (4% liposomal lidocaine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EMLA cream (eutectic mixture of local anesthetics)
Number of subjects: 0
Study: 11075988

Group type: COMPARATOR
Intervention: Standard enteral formula
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Immunonutrition (enteral formula enriched with arginine, omega‐3 fatty acids, and RNA)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 212
Study: 9288457

Group type: COMPARATOR
Intervention: Conventional, thin, 38% water, pHEMA soft contact lens (SCL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Experimental high Dk (EHD), 20%-water soft contact lens
Number of subjects: 6

Group type: COMPARATOR
Intervention: No contact lens wear
Number of subjects: 6
Study: 8312148

Group type: EXPERIMENTAL
Intervention: Topical agents for cutaneous infections in immunocompetent patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic therapy for recurrent vulvovaginal candidiasis and oroesophageal candida infections
Number of subjects: 0
Study: 3552359

Group type: EXPERIMENTAL
Intervention: Sunitang (250, 500, and 1000 mg single oral doses)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sunitang (additional treatment alongside original medications)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (original medications only)
Number of subjects: 87
Study: 31948736

Group type: EXPERIMENTAL
Intervention: Multimedia module (MM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Handout (HO)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both HO and MM
Number of subjects: 35
Study: 29230716

Group type: EXPERIMENTAL
Intervention: Visnadine spray (ReFeel® spray), 2 puffs in the vulvar area, 10 minutes before sexual stimulation, for 30 days (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PL), 2 puffs in the vulvar area, 10 minutes before sexual stimulation, for 30 days (n=28)
Number of subjects: 60
Study: 27506667

Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 25 μg vitamin D3
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 24785854

Group type: EXPERIMENTAL
Intervention: Continuous use of oral contraceptive pills (OCPs)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Cyclic use of oral contraceptive pills (OCPs)
Number of subjects: 358
Study: 22343992

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 30
Study: 19594305

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18609692

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated scalpel (US)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monopolar electrocautery shovel (ES)
Number of subjects: 40
Study: 16053590

Group type: EXPERIMENTAL
Intervention: Implementation strategy 1
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Implementation strategy 2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Implementation strategy 3
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Implementation strategy 4
Number of subjects: 51
Study: 12434952

Group type: EXPERIMENTAL
Intervention: 10,000/microL platelet transfusion threshold
Number of subjects: 159

Group type: COMPARATOR
Intervention: 20,000/microL platelet transfusion threshold
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 10,000/microL and 20,000/microL platelet transfusion thresholds
Number of subjects: 159
Study: 10484572

Group type: EXPERIMENTAL
Intervention: OC E + P
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: OC P
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 9

Group type: COMPARATOR
Intervention: Follicular phase
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High plasma 17beta-estradiol concentration
Number of subjects: 9
Study: 8835619

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) at a dose of 5 mg/kg body weight in addition to insulin therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (insulin therapy only)
Number of subjects: 22
Study: 2363545

Group type: EXPERIMENTAL
Intervention: Clinical complications (bronchitis)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Radiological complications (atelectasis)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Hypoxaemia (PaO2 less than 70 mmHg)
Number of subjects: 146
Study: 7402803

Group type: EXPERIMENTAL
Intervention: Early and extended postpartum contact
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Paraprofessional home visits
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 321
Study: 31233129

Group type: EXPERIMENTAL
Intervention: Drug disposal bag provision
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard postoperative discharge instructions only (Control)
Number of subjects: 202
Study: 28054389

Group type: EXPERIMENTAL
Intervention: High-level exposures (HLE) at 100,000 cm-3
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-level exposures (LLE) at particle background (3000 cm-3)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both HLE and LLE
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study: 25488504

Group type: EXPERIMENTAL
Intervention: Chronic care intervention consisting of a primary care provider (PCP) brief intervention, referral to addiction services, and ongoing support from a care manager (CM) for 6 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study: 23921777

Group type: EXPERIMENTAL
Intervention: Enhanced Brief Lifestyle Counseling
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 390

Group type: COMPARATOR
Intervention: Brief Lifestyle Counseling
Number of subjects: 390
Study: 21292760

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo (as-needed β-agonist)
Number of subjects: 1041
Study: 19681417

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy (10 manual breaths with peak inspiratory pressure of 40 cmH2O plus positive end-expiratory pressure of 15 cmH2O)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (tidal volume 10 ml/kg with no positive end-expiratory pressure)
Number of subjects: 50
Study: 17475552

Group type: EXPERIMENTAL
Intervention: Exercise training (n=15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untrained (n=12)
Number of subjects: 27
Study: 15213528

Group type: EXPERIMENTAL
Intervention: Furlow palatoplasty
Number of subjects: 30
Study: 11576414

Group type: EXPERIMENTAL
Intervention: Cimetidine and levamisole (combination treatment)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cimetidine alone (control)
Number of subjects: 44
Study: 9531852

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8034203

Group type: EXPERIMENTAL
Intervention: O‐(beta‐hydroxyethyl)‐rutosides (HR) 250 mg 4 times daily (1 g/day), UK, n = 19 patients
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: O‐(beta‐hydroxyethyl)‐rutosides (HR) 300 mg 3 times daily (900 mg/day), FRG and Belgium, n = 55
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: O‐(beta‐hydroxyethyl)‐rutosides (HR) 300 mg 4 times daily (1,200 mg/day), The Netherlands, n = 30
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: O‐(beta‐hydroxyethyl)‐rutosides (HR)
Number of subjects: 104
Study: 2808264

Group type: EXPERIMENTAL
Intervention: Suicide awareness curriculum provided to 215 students
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Suicide awareness curriculum
Number of subjects: 471
Study: 786673

Group type: EXPERIMENTAL
Intervention: Oxprenolol 20 mg
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Oxprenolol 40 mg
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Oxprenolol 60 mg
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Oxprenolol 80 mg
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Oxprenolol with dihydralazine and hydrochlorothiazide
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Dihydralazine 30 mg
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 30 mg
Number of subjects: 329
Study: 30950450

Group type: EXPERIMENTAL
Intervention: Various adjuvant treatments including locoregional and systemic therapies as per trials mentioned (MAGIC, Intergroup 0116, ACTS‐GC, CLASSIC, ARTIST, CRITICS)
Number of subjects: 0
Study: 28159608

Group type: EXPERIMENTAL
Intervention: C-Tb skin test
Number of subjects: 979

Group type: COMPARATOR
Intervention: TST
Number of subjects: 979
Study: 25863779

Group type: COMPARATOR
Intervention: MMP‐13 in patients with alcoholic liver cirrhosis (stage A, B, C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glutamic acid and glutamine concentrations in patients with alcoholic liver cirrhosis (stage A, B, C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plasma levels of valine, isoleucine, leucine, and tryptophan in patients with alcoholic liver cirrhosis (stage C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: MMP‐1 in patients with alcoholic liver cirrhosis
Number of subjects: 60
Study: 23211475

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone for 16 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21255472

Group type: EXPERIMENTAL
Intervention: Glucose (intragastric infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructose (intragastric infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Artificial Sweeteners (AS: aspartame, acesulfame K, sucralose) (intragastric infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2-deoxy-d-glucose (intragastric infusion)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 18495285

Group type: EXPERIMENTAL
Intervention: liraglutide 0.1mg
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: liraglutide 0.3mg
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: liraglutide 0.6mg
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: liraglutide 0.9mg
Number of subjects: 226
Study: 15798546

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg) and succinylcholine (0.75 mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Etomidate (0.15 mg/kg) and succinylcholine (0.75 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both groups (Propofol and Etomidate)
Number of subjects: 25
Study: 14514937

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mg once daily in the morning (09.00 hours)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mg once daily in the evening (21.00 hours)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 10651681

Group type: EXPERIMENTAL
Intervention: Desflurane (6% end-tidal concentration in oxygen for 30 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane (1.1% end-tidal concentration in oxygen for 30 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subgroup of 10 patients with pulmonary artery catheters
Number of subjects: 30
Study: 8673580

Group type: EXPERIMENTAL
Intervention: Group A: simulated wrestling tournament, four 5‐min wrestling bouts after a 5% body weight loss and 17 h repletion period
Number of subjects: 12

Group type: COMPARATOR
Intervention: Group B: 5% weight loss through energy restriction (1,141 kcal/day), exercise, fluid restriction, and dehydration methods (sauna) > 72 h
Number of subjects: 12
Study: 1631878

Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride 0.5% solution, 10 ml/h
Number of subjects: 24

Group type: COMPARATOR
Intervention: NaCl 0.9% solution, 10 ml/h
Number of subjects: 24
Study: 6397856

Group type: EXPERIMENTAL
Intervention: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% in muco-adhesive foam base
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simple aqueous foam (B.P.)
Number of subjects: 40
Study: 31795359

Group type: EXPERIMENTAL
Intervention: Dose-dense weekly paclitaxel (80 mg/m2) and low-dose triweekly cisplatin (20 mg/m2)
Number of subjects: 32
Study: 29466093

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention
Number of subjects: 588

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 588
Study: 27206459

Group type: EXPERIMENTAL
Intervention: Internet access with IT support
Number of subjects: 118
Study: 24614605

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMT)
Number of subjects: 0
Study: 22681227

Group type: EXPERIMENTAL
Intervention: K101
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 20453678

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 18820248

Group type: EXPERIMENTAL
Intervention: Prewarming using the Bair Paws system for 60 min at 38 degrees C
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Prewarming using the Bair Paws system
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 68
Study: 16028386

Group type: EXPERIMENTAL
Intervention: Profenid administered per rectum (100 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Profenid administered intravenously (100 mg)
Number of subjects: 40
Study: 12601511

Group type: EXPERIMENTAL
Intervention: Pelvicol implant (n=74)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT) (n=68)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Pelvicol implant
Number of subjects: 142
Study: 10684389

Group type: COMPARATOR
Intervention: Patch testing
Number of subjects: 401

Group type: COMPARATOR
Intervention: Day of application
Number of subjects: 401

Group type: COMPARATOR
Intervention: Day of reading
Number of subjects: 401

Group type: COMPARATOR
Intervention: Positive patch tests
Number of subjects: 401
Study: 9248868

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 26
Study: 8403908

Group type: EXPERIMENTAL
Intervention: Norgestrel-based (NG) OC
Number of subjects: 892

Group type: COMPARATOR
Intervention: Norethindrone acetate-based (NA) OC
Number of subjects: 892
Study: 3861138

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2-gel (0.5 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: COMPARATOR
Intervention: PGE2 vaginal suppositories (2.0 mg)
Number of subjects: 38
Study: 31960537

Group type: EXPERIMENTAL
Intervention: Nurse-led structured counselling session (30 minutes before and 24 hours after PCI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nurse-led structured counselling session
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard pre-procedure information (control group)
Number of subjects: 80
Study: 29950742

Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (conventional hemostasis)
Number of subjects: 34
Study: 27562067

Group type: EXPERIMENTAL
Intervention: High intensity exercise (85% HRmax)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (65% HRmax)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (45% HRmax)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: All exercise groups
Number of subjects: 121
Study: 25298575

Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 mg, 5 mg, 10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metoprolol succinate (25 mg, 50 mg, 100 mg)
Number of subjects: 60
Study: 23171672

Group type: EXPERIMENTAL
Intervention: Minimum strategy (MS): dissemination of the IBSM program
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Intermediate strategy (IS): MS + start-up support for professionals
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Extended strategy (ES): IS + additional training and ongoing support for professionals
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness measurements
Number of subjects: 420
Study: 21134821

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy doublet fluoropyrimidine (5-FU or capecitabine) plus cisplatin (FP) every three weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 100
Study: 18315508

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 10
Study: 15948255

Group type: EXPERIMENTAL
Intervention: Lansoprazole combined with tepreton (group A)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lansoprazole (group B)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Tepreton (group C)
Number of subjects: 3
Study: 12578781

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 40 mg, administered orally, three times daily for 4 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (identical capsules filled with 40 mg fructose)
Number of subjects: 27
Study: 10547209

Group type: EXPERIMENTAL
Intervention: Insulin added to glibenclamide therapy during phase I (4 months)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo after sulphonylurea withdrawal during phase II (1-4 months)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Glibenclamide during phase II (1-4 months)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: SU responders defined by protocol (FBG increase > or =40%)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: GAD-antibody status
Number of subjects: 175
Study: 8915222

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1801688

Group type: EXPERIMENTAL
Intervention: GM-CSF after chemotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GM-CSF as a priming agent 24 hours prior to chemotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (historic)
Number of subjects: 36
Study: 6335039

Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 7